Recurrent Small Cell Lung Cancer (SCLC) Unknown Status Phase 2 Trials for Bendamustine (DB06769)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Recurrent Small Cell Lung Cancer / Refractory Small cell lung cancer / Small Cell Lung Cancer Recurrent

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Unknown Status2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00168922Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)Treatment